Glycans Marker for Gastric Cancer - - Chromatography Online
Glycans Marker for Gastric Cancer

The Column
Volume 10, Issue 2, pp. 67

A team of researchers from the University of California Davis (California, USA) in collaboration with scientists in Mexico and South Korea have performed liquid chromatography–mass spectrometry (LC–MS) to find that sugars added to proteins could be an indicator of gastric cancer.

The study published in the journal Cancer Prevention Research suggests that glycans (sugars) found in blood serum could be a potential clinical biomarker. The disease kills approximately 700,000 people a year, largely affecting the population of Latin America, Asia, and Eastern Europe. The disease is often the result of a Helicobacter pylori infection, which can also result in asymptomatic gastritis and duodenal ulcers. However, there is no definitive test to determine whether or not the infection will lead to the onset of gastric cancer.

Glycans are added to proteins via the process of glycosylation, that is in a sense the postal service of the cell. The addition of glycans to a protein can be regulatory, in the case of an enzyme, or can act to direct it through the membrane transport system so that it reaches its target destination in the cell. This can be misregulated in some cancers, disrupting regular cell function.

The researchers were interested to learn if the level of glycans in blood serum varied between patients with gastritis, ulcers, or cancer. LC–MS was performed on 72 samples taken from patients in Mexico City. There were 19 significant changes in glycan levels, with three that could be used to differentiate between gastric cancer and gastritis.

Jay Solnick, lead author and professor at the Center for Comparative Medicine at UC Davis, said: “We showed statistically significant differences between the serum glycan profiles of patients with gastric cancer and those with gastritis.” He added: “This is the first time anyone has looked at whether serum glycans could be used to detect gastric cancer.” The next step for the researchers is to use this statistic difference to develop a diagnostic test. — —B.D.

DOI: 10.1158/1940-6207

This article first appeared in The Column. Click here to view that issue.


blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:



Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: When Bad Things Happen to Good Food: Applications of HPLC to Detect Food Adulteration

Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: HPLC for Characterization and Quality Control of Therapeutic Monoclonal Antibodies

MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis

LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: How Much Can I Inject? Part I: Injecting in Mobile Phase

More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>

Source: The Column,
Click here